Literature DB >> 4318009

Severe illnesses due to adenovirus type 7 in children.

J Steen-Johnsen, I Orstavik, A Attramadal.   

Abstract

Entities:  

Mesh:

Year:  1969        PMID: 4318009     DOI: 10.1111/j.1651-2227.1969.tb04700.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


× No keyword cloud information.
  8 in total

1.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

2.  Specialty conference: potpourri of adenoviral infections.

Authors:  J D Connor; R M Buchta; F DeGenaro; M A Fletcher; W L Nyhan
Journal:  West J Med       Date:  1974-01

3.  Genome analysis of South American adenovirus strains of serotype 7 collected over a 7-year period.

Authors:  A Kajon; G Wadell
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

4.  Hyperlucent lung: long-term complication of adenovirus type 7 pneumonia.

Authors:  L Spigelblatt; R Rosenfeld
Journal:  Can Med Assoc J       Date:  1983-01-01       Impact factor: 8.262

5.  Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia.

Authors:  P D Sly; M E Soto-Quiros; L I Landau; I Hudson; H Newton-John
Journal:  Arch Dis Child       Date:  1984-10       Impact factor: 3.791

6.  Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children.

Authors:  D M Becroft
Journal:  J Clin Pathol       Date:  1971-02       Impact factor: 3.411

7.  Causes and management of bronchiolitis with chronic obstructive features.

Authors:  I G Hodges; A D Milner; R C Groggins; G M Stokes
Journal:  Arch Dis Child       Date:  1982-07       Impact factor: 3.791

8.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.